This study is in progress, not accepting new patients
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Summary
- Eligibility
- for people ages 18-130 (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Acerta Pharma BV
- ID
- NCT02112526
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated